PEMF for Cervical
Myelopathy.

July 2026 · 11 min read · Neurology · Spine Protocol

Myelopathy vs Radiculopathy: A Critical Distinction

Cervical radiculopathy — the more commonly discussed condition — involves compression of a single nerve root exiting the cervical spine. It produces dermatomal pain, sensory changes, and weakness in a specific arm distribution. Cervical myelopathy is categorically different: here, the spinal cord itself is compressed within the bony cervical canal, producing a diffuse neurological syndrome affecting the entire body below the level of compression.

The distinction matters for PEMF protocol design. Radiculopathy targets are localized (one nerve root, one dermatome). Myelopathy requires a broader, neuroprotective approach aimed at the compressed cord segment and the descending corticospinal tracts — with measurable neurophysiological outcomes via somatosensory evoked potentials (SSEPs) rather than simple pain scoring alone.

Causes and Severity Classification

Cervical myelopathy results from progressive reduction of the cervical spinal canal diameter below the critical threshold of approximately 10 mm (normal: 14–22 mm). The four most common causes:

• Cervical spondylotic myelopathy (CSM): Most common cause (65–80%). Multisegment disc degeneration, osteophyte formation, and hypertrophied ligamentum flavum progressively narrow the canal over years to decades.
• Disc herniation with cord compression: Acute or subacute onset. Single or multi-level central disc protrusion encroaching on the cord.
• Ossification of the posterior longitudinal ligament (OPLL): More prevalent in Asian populations (2–3% of Japanese, Korean populations; less data for Southeast Asia). Calcification of the PLL causes progressive canal narrowing.
• Inflammatory (rheumatoid arthritis, ankylosing spondylitis): Atlantoaxial instability or subaxial subluxation compressing cord.

The modified Japanese Orthopaedic Association (mJOA) scale (0–17) is the international standard for myelopathy severity. The minimum clinically important difference (MCID) for treatment is 2 points. Conservative management (without surgery) is appropriate for mild myelopathy (mJOA ≥ 15) and selected moderate cases — comprising approximately 85% of presentations at the time of diagnosis.

The Neurophysiological Evidence: SSEP Data

The strongest direct evidence for PEMF in spinal cord dysfunction comes from a randomized controlled trial (PMID 23083041, n=40 patients with disc herniation and nerve root/cord involvement, VAS P=0.024, Oswestry Disability Index P<0.001, 9 of 10 Oswestry domains improved). Critically for myelopathy, this study also demonstrated bilateral SSEP normalization:

• Cortical SSEP latency: significant improvement p=0.016–0.022 (both lower extremities)
• SSEP amplitude: significant improvement p=0.001–0.002

SSEP normalization indicates measurable improvement in spinal cord conduction velocity — not merely symptom relief. This is the neurophysiological footprint of neuroprotection, making PEMF one of the few non-surgical interventions with objective cord function data in the compressive spine literature.

Four PEMF Mechanisms in Cervical Myelopathy

1. Neuroprotection: BDNF and NGF Upregulation

Chronic cord compression reduces neurotrophic factor expression in the compressed segment, accelerating oligodendrocyte apoptosis and axonal demyelination. PEMF at 10–25 Hz upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) at the compressed level — the same mechanism demonstrated in post-stroke rehabilitation, traumatic brain injury, and spinal cord injury protocols. BDNF sustains myelin production, promotes axonal sprouting in partially injured tracts, and reduces programmed cell death in spinal interneurons.

2. Anti-Inflammatory: Adenosine-A2A Pathway

Cord compression triggers a sustained neuroinflammatory cascade: microglial activation, astrocyte hypertrophy, and elevated IL-1β/TNF-α in the compressed cord parenchyma. The adenosine-A2A receptor activation mechanism — anchor of the 2025 multicenter RCT (PMC11914662, n=91, 36% pain reduction vs 10% standard care, 55% medication reduction) — suppresses NF-κB-mediated neuroinflammation in the cord itself, reducing secondary injury progression independent of the primary mechanical compression.

3. Perivertebral Microcirculation

Cord compression also impairs the radiculomedullary arteries supplying the compressed segment. PEMF at 8–25 Hz improves perivertebral microcirculation via eNOS upregulation and VEGF-mediated capillary density increase — reducing the ischemic contribution to myelopathic symptoms (documented in PMC7401674, cervical non-specific neck pain n=63, 5 outcome domains improved at 12 weeks).

4. Paraspinal Muscle Normalization

Cervical myelopathy is invariably associated with compensatory paraspinal muscle hypertonicity and altered cervical alignment that worsens canal compromise dynamically during flexion. PEMF at the cervicothoracic junction reduces upper trapezius and deep cervical extensor tone — demonstrated in PMC12467020 (n=30, magnetic field therapy superior to massage for upper trapezius tone p=0.015, η²=0.28, large effect) — reducing the dynamic component of canal compromise and improving neutral posture maintenance.

Clinical Protocol (Mild–Moderate Myelopathy, mJOA ≥ 12)

Session duration: 30–40 minutes. Patient positioning: sitting or prone (avoid cervical hyperextension). PEMF is used as an adjunct to cervical traction, physiotherapy, and neurosurgical surveillance — not as a substitute for surgical decompression in moderate-severe cases (mJOA < 12). Neurological status should be re-assessed clinically (mJOA, Nurick) every 4 weeks.

PEMF vs Conventional Conservative Treatments

Philippine Market Context

The Philippines faces a convergence of factors driving cervical myelopathy burden. The working-age population (80 million) is increasingly exposed to cervical spondylosis risk factors: 7.3 million motorcyclists with sustained neck hyperextension, an estimated 1.3 million BPO workers with prolonged screen-induced forward head posture, and a rapidly aging population (7 million+ over 60) in whom spondylotic myelopathy is the leading spinal cord disorder.

Diagnostic and surgical access is severely limited outside Metro Manila. Neurosurgical consultation costs ₱3,000–₱8,000; MRI is ₱8,000–₱25,000 (PhilHealth partial coverage). Anterior cervical discectomy and fusion (ACDF) — the definitive surgical intervention — costs ₱200,000–₱500,000 and is only available in tertiary centers. Fewer than 200 neurosurgeons are registered outside major urban centers.

PEMF fills a critical gap: for the majority of myelopathy patients who are mild (mJOA ≥ 15) or who are awaiting surgery, a ₱1,500–₱2,500 per session protocol provides measurable neuroprotective benefit while managing the 6–18 month waitlist that is standard in provincial settings.

Important Clinical Boundaries

PEMF is not appropriate as sole therapy for moderate-to-severe myelopathy (mJOA < 12 / Nurick ≥ 3). Patients with progressive neurological deterioration — worsening gait, new sphincter dysfunction, rapid hand weakness — require urgent neurosurgical referral. PEMF in this context should be positioned as pre-operative neuroprotection or post-operative rehabilitation adjunct, not as a reason to defer surgery.

Clinicians should monitor for the "myelopathy step sign" — sudden neurological decline following minor trauma or cervical flexion — which represents a medical emergency and immediate surgical indication regardless of PEMF treatment status.

Contraindications

• Absolute: Active pacemaker or implanted spinal cord stimulator in the cervical/upper thoracic region. Active malignancy involving the cervical spine (cord compression from metastasis — surgical/oncology priority). Pregnancy.
• Relative: Atlantoaxial instability (>3.5 mm dynamic subluxation on flexion-extension X-ray) — confirm stability before cervical coil placement. Acute myelopathic episode (acute deterioration) — defer until neurological status stabilized. Cervical fixation hardware (confirm non-ferrous titanium before treating over hardware; stainless steel — defer to treating surgeon).
• Positioning precaution: Avoid cervical hyperextension during treatment — this dynamically reduces canal diameter and transiently worsens cord compression. Treat in neutral to slight flexion posture.

Frequently Asked Questions

How does cervical myelopathy differ from a herniated disc in the neck?

A cervical herniated disc (radiculopathy) compresses one nerve root, producing pain, numbness, and weakness in one arm in a dermatomal pattern. Cervical myelopathy involves cord compression and presents with bilateral symptoms, gait disturbance, hand clumsiness affecting both hands, hyperreflexia, and in advanced cases, bladder dysfunction. The treatments differ accordingly: radiculopathy often resolves with conservative care; myelopathy requires neurosurgical monitoring and, in moderate-severe cases, decompression surgery.

Is PEMF safe alongside cervical traction?

Yes. PEMF and cervical mechanical traction address different aspects of the condition and are complementary. Traction mechanically distracts the disc space and reduces dynamic canal compromise; PEMF addresses neuroinflammation, neuroprotection, and paraspinal hypertonicity. Sequence recommendation: PEMF before traction (reduces paraspinal tone, improving traction tolerance) or immediately after (reduces post-traction soreness).

What outcome measure should clinics track?

The mJOA scale (0–17) is the gold standard and takes 3 minutes to complete in clinic. Supplement with VAS for neck and arm pain, grip strength measurement (hand dynamometer), and Nurick gait assessment. SSEP testing is appropriate in specialized centers for objective neurological monitoring. A minimum clinically important difference (MCID) of 2 mJOA points over 12 weeks represents a meaningful treatment response.